

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/554,036	Applicant: Yevgeni Besidski
Filing Date: October 20, 2005	Attorney Docket No.: 101023-1P US
Examiner: Laura Lynne Stockton	Group Art Unit : 1626
Customer No.: 22466	Confirmation No.: 7802
Title: Heterocyclic Amides Exhibiting and Inhibitory Activity at the Vanilloid Receptor 1 (vr1)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

Responsive to the restriction requirement dated July 23, 2008, Applicants elect Group II.


We elect the single species in example 10, (4-Bromo-N-[2-(hydroxymethyl)-1,3-benzothiazol-5-yl]-2-methylbenzamide).

Applicants expressly reserve the right to prosecute claims of the non-elected inventions in future divisional or continuation applications.

Applicants believe that no fees are due; however, if any fees are due, authorization is given to charge Deposit Account 260166 for the required fees.

Applicants earnestly solicit prompt examination on the merits.

Respectfully submitted,



Name: Karen H. Kondrad  
Dated: August 25, 2008  
Reg. No.: 38,212  
Phone No.: 886-8975

Global Intellectual Property, Patents  
AstraZeneca  
1800 Concord Pike,  
Wilmington, DE-19850-5437